The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocytocidal Activity
- 1 October 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (10) , 4080-4085
Abstract
Malaria continues to be a major global health problem, but only a limited arsenal of effective drugs is available. None of the antimalarial compounds commonly used clinically kill mature gametocytes, which is the form of the parasite that is responsible for malaria transmission. The parasite that causes the most virulent human malaria, Plasmodium falciparum , has a 48-h asexual cycle, while complete sexual differentiation takes 10 to 12 days. Once mature, stage V gametocytes circulate in the peripheral blood and can be transmitted for more than a week. Consequently, if chemotherapy does not eliminate gametocytes, an individual continues to be infectious for several weeks after the clearance of asexual parasites. The work reported here demonstrates that nanomolar concentrations of the proteasome inhibitor epoxomicin effectively kill all stages of intraerythrocytic parasites but do not affect the viability of human or mouse cell lines. Twenty-four hours after treatment with 100 nM epoxomicin, the total parasitemia decreased by 78%, asexual parasites decreased by 86%, and gametocytes decreased by 77%. Seventy-two hours after treatment, no viable parasites remained in the 100 or 10 nM treatment group. Epoxomicin also blocked oocyst production in the mosquito midgut. In contrast, the cysteine protease inhibitors epoxysuccinyl- l -leucylamido-3-methyl-butane ethyl ester and N -acetyl- l -leucyl- l -leucyl- l -methioninal blocked hemoglobin digestion in early gametocytes but had no effect on later stages. Moreover, once the cysteine protease inhibitor was removed, sexual differentiation resumed. These findings provide strong support for the further development of proteasome inhibitors as antimalaria agents that are effective against asexual, sexual, and mosquito midgut stages of P. falciparum .Keywords
This publication has 28 references indexed in Scilit:
- Marine Actinomycetes: A New Source of Compounds against the Human Malaria ParasitePLOS ONE, 2008
- Effect of protease inhibitors on exflagellation in Plasmodium falciparumMolecular and Biochemical Parasitology, 2008
- Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparumNature Chemical Biology, 2008
- Primaquine Clears Submicroscopic Plasmodium falciparum Gametocytes that Persist after Treatment with Sulphadoxine-Pyrimethamine and ArtesunatePLOS ONE, 2007
- Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the ProteasomeCancer Research, 2007
- Targeted disruption of Plasmodium falciparum cysteine protease, falcipain 1, reduces oocyst production, not erythrocytic stage growthMolecular Microbiology, 2004
- Data-Mining Approaches Reveal Hidden Families of Proteases in the Genome of Malaria ParasiteGenome Research, 2003
- A Comprehensive View on Proteasomal Sequences: Implications for the Evolution of the ProteasomeJournal of Molecular Biology, 2003
- Structure-Activity Relationships for Inhibition of Cysteine Protease Activity and Development of Plasmodium falciparum by Peptidyl Vinyl SulfonesAntimicrobial Agents and Chemotherapy, 2003
- The ProteasomeAmerican Journal of Clinical Pathology, 2001